Adverse findings from some early- to mid-2022 US Food and Drug Administration site inspections have been trickling out, providing an inkling of how drug manufacturing quality may have declined during the COVID-19 pandemic inspection hiatus in two areas of great interest to the agency – sterile manufacturing of injectable drugs and manufacturing of active pharmaceutical ingredients.
This edition of the Quality Lowdown examines some of those findings that are not especially uplifting.